Stockscreener 앱 받기
4.45
6.12%
-0.29
시간 외 거래:
4.50
0.05
+1.12%
전일 마감가:
$4.74
열려 있는:
$4.75
하루 거래량:
2.23M
Relative Volume:
0.96
시가총액:
$914.30M
수익:
순이익/손실:
$-129.48M
주가수익비율:
-7.9692
EPS:
-0.5584
순현금흐름:
$-106.97M
1주 성능:
-9.55%
1개월 성능:
-13.26%
6개월 성능:
-21.10%
1년 성능:
+24.30%
1일 변동 폭
$4.44
$4.77
1주일 범위
$4.44
$5.02
52주 변동 폭
$3.495
$7.005
사바라 Stock (SVRA) Company Profile
명칭
Savara Inc
전화
51285113796
주소
6836 BEE CAVE ROAD, AUSTIN, TX
Compare SVRA vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SVRA
Savara Inc
|
4.45 | 914.30M | 0 | -129.48M | -106.97M | -0.5584 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
사바라 Stock (SVRA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-10-07 | 개시 | JP Morgan | Overweight |
| 2026-04-24 | 재개 | Oppenheimer | Outperform |
| 2025-10-20 | 개시 | Wells Fargo | Overweight |
| 2025-08-15 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-12-20 | 개시 | Wells Fargo | Overweight |
| 2024-11-13 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2024-02-15 | 개시 | JMP Securities | Mkt Outperform |
| 2023-11-07 | 개시 | Guggenheim | Buy |
| 2023-05-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-03-31 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-03-16 | 개시 | Piper Sandler | Overweight |
| 2021-03-15 | 개시 | Oppenheimer | Outperform |
| 2019-06-13 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-13 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-13 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2018-08-13 | 재개 | ROTH Capital | Neutral |
| 2018-01-03 | 개시 | Ladenburg Thalmann | Buy |
| 2017-09-27 | 재개 | ROTH Capital | Buy |
| 2017-09-22 | 개시 | Jefferies | Buy |
| 2017-09-11 | 개시 | JMP Securities | Mkt Outperform |
모두보기
사바라 주식(SVRA)의 최신 뉴스
Savara Inc CCO Braden Parker Withholds 29,323 Shares for RSU Tax Settlement - Kalkine Media
Form 4 Savara Inc For: 25 September By Investing.com - Investing.com Nigeria
Savara Awaits FDA Verdict: Will Molbreevi Pass Regulatory Muster? - RTTNews
Savara Inc (YB4P.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Savara, Inc. (SVRA) Stock Analysis: Exploring a Potential 101.80% Upside in Biotech Investment - DirectorsTalk Interviews
Savara (SVRA) Institutional Ownership 2026 - MarketBeat
When Can We Expect A Profit From Savara Inc. (NASDAQ:SVRA)? - Moomoo
Will Long-Term IMPALA-2 aPAP Data at ERS 2026 Change Savara's (SVRA) Narrative - simplywall.st
Savara stock holds steady as investors focus on lead lung therapy - ad-hoc-news.de
Savara Grants Equity Awards to Eight New Employees - MyChesCo
Piper Sandler Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $16 - Moomoo
Savara (SVRA) Results at a Glance: Profit Per Share Falls Below Its Benchmark for This Review; Market Response: Shares Finish 0.72% Higher for the Current SessionProfit Margin Analysis - vinanet.vn
Does Phase 3 IMPALA-2 aPAP Data at ERS 2026 Change The Bull Case For Savara (SVRA)? - simplywall.st
Savara presents molgramostim data at ERS Congress in September By Investing.com - Investing.com Canada
Savara presents molgramostim data at ERS Congress in September By Investing.com - Investing.com Nigeria
Savara Announces Encore Presentations of Results from the Phase 3 Clinical Trial of Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (APAP) at the European Respiratory Society (ERS) Congress 2026 - Yahoo Finance
Why Savara (SVRA) Is Getting Attention Today - Sahm
Savara (SVRA) Trading: Posts a 1.82% Gain to $5.59 in Latest Trading; Next Test: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateWyckoff Spring - dars.gov.et
Savara (SVRA) Trading: Posts a 1.82% Gain to $5.59 in Latest Trading; Next Test: the Current Price Sits Inside the Supplied Technical Range in the Current UpdateMcClellan Summation - vinanet.vn
Savara Announces New Employment Inducement GrantAugust 20, 2026 - BioSpace
Savara Announces New Employment Inducement Grant - Business Wire
Savara Announces New Employment Inducement Grant - Yahoo Finance
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Outlook Update - dars.gov.et
Savara (SVRA) Quarterly Results: The Bottom-Line Figure Trails Its Comparison under the Current Snapshot; Trading Response: Shares Move 3.91% Higher for the Current SessionEarnings Beat Streak - vinanet.vn
A Quick Look at Today's Ratings for Savara(SVRA.US), With a Forecast Between $9 to $11 - Moomoo
Savara (SVRA) Advances 2.09% to $5.38 as Aerosol Therapy Momentum BuildsStock Analysis - vinanet.vn
SVRA Q1 2026 Earnings: Wider-than-Expected Loss Reflects Clinical-Stage Pipeline InvestmentPeak Earnings Alert - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Triple Top - vinanet.vn
Savara Inc. (SVRA) Gains 2.09% to $5.38, Holding Support at $5.11Head and Shoulders - dars.gov.et
Walleye Capital LLC Invests $1.53 Million in Savara Inc. $SVRA - MarketBeat
Savara (NASDAQ:SVRA) Stock Rating Lowered by Wall Street Zen - MarketBeat
HC Wainwright Brokers Lower Earnings Estimates for Savara - MarketBeat
Savara (NASDAQ:SVRA) Stock Price Down 5.4%What's Next? - MarketBeat
HC Wainwright Has Pessimistic View of Savara FY2029 Earnings - marketbeat.com
Wells Fargo Reaffirms Their Buy Rating on Savara (SVRA) - The Globe and Mail
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
How Investors Are Reacting To Savara (SVRA) Wider Q2 Loss And New US$108 Million Share Shelf - simplywall.st
Savara Inc. (SVRA) Advances 1.17% as Rare Disease Focus Draws Continued Interest — Resistance at $5.91 in SightPrice Momentum Stocks - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Revenue Weighted - Vinanet
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Volatility Term Structure - dars.gov.et
Wells Fargo Maintains Savara(SVRA.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Savara Inc. (SVRA) Slips 2.79% as Shares Test Key Support at $5.29Collar Trade - dars.gov.et
SAVARA Q2 EPS USD -0.16 - Moomoo
Savara Q2 loss widens to $40M on surging commercial costs - scanx.trade
Savara Inc (SVRA) Advances MOLBREEVI Launch Amid High Price-to-S - GuruFocus
Savara (NASDAQ:SVRA) Releases Quarterly Earnings Results, Misses Expectations By $0.02 EPS - MarketBeat
Savara Inc. Announces Q2 2026 Financial Results with Increased Net Losses - Kalkine Media
Savara Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Savara Q2 loss widens as operating expenses rise - TradingView
Savara Inc 2Q 2026: Net loss $(40.2M), EPS $(0.16) — 10-Q Summary - TradingView
사바라 (SVRA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
사바라 주식 (SVRA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Lowrance David L | Chief Financial Officer |
Jun 22 '26 |
Sale |
5.68 |
394,528 |
2,241,432 |
536,032 |
| Lowrance David L | Officer |
Jun 22 '26 |
Proposed Sale |
5.65 |
394,528 |
2,229,000 |
0 |
| Lowrance David L | Chief Financial Officer |
Mar 18 '26 |
Option Exercise |
1.60 |
366,747 |
588,455 |
552,550 |
| McCracken Joseph S | Director |
Feb 16 '26 |
Option Exercise |
1.76 |
1,807 |
3,180 |
302,644 |
| RAMSAY DAVID A | Director |
Dec 19 '25 |
Sale |
6.06 |
20,000 |
121,220 |
2,533,642 |
| RAMSAY DAVID A | Director |
Dec 18 '25 |
Proposed Sale |
6.11 |
20,000 |
122,200 |
0 |
| Elam Nevan C | Director |
Dec 02 '25 |
Option Exercise |
1.46 |
5,860 |
8,556 |
68,360 |
| Hawkins Richard J | Director |
Nov 14 '25 |
Option Exercise |
1.46 |
5,860 |
8,556 |
121,326 |
5.15%
1.31%
자본화:
|
볼륨(24시간):